COST-EFFECTIVENESS ANALYSIS OF ORAL SEMAGLUTIDE AS THE SECOND-LINE AND THIRD-LINE TREATMENT FOR TYPE 2 DIABETES PATIENT

被引：0
|
作者：
Tan, E. C. H. [1 ]
Yang, M. C. [2 ]
机构：
[1] China Med Univ, Dept Hlth Serv Adm, Taichung, Taiwan
[2] Natl Taiwan Univ, Taipei, Taiwan
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 12期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE15
引用
收藏
页码：S52 / S53
页数：2
相关论文
共 50 条
  • [1] Patient stratification for determining optimal second-line and third-line therapy for type 2 diabetes: the TriMaster study
    Beverley M. Shields
    John M. Dennis
    Catherine D. Angwin
    Fiona Warren
    William E. Henley
    Andrew J. Farmer
    Naveed Sattar
    Rury R. Holman
    Angus G. Jones
    Ewan R. Pearson
    Andrew T. Hattersley
    [J]. Nature Medicine, 2023, 29 : 376 - 383
  • [2] Patient stratification for determining optimal second-line and third-line therapy for type 2 diabetes: the TriMaster study
    Shields, Beverley M. M.
    Dennis, John M. M.
    Angwin, Catherine D. D.
    Warren, Fiona
    Henley, William E. E.
    Farmer, Andrew J. J.
    Sattar, Naveed
    Holman, Rury R. R.
    Jones, Angus G. G.
    Pearson, Ewan R. R.
    Hattersley, Andrew T. T.
    [J]. NATURE MEDICINE, 2023, 29 (02) : 376 - 383
  • [3] COST-EFFECTIVENESS ANALYSIS OF SECOND-LINE AND THIRD-LINE ANTIDIABETIC DRUGS IN TYEP 2 DIABETES: AN EMPIRICAL, POPULATION-BASED OBSERVATIONAL STUDY FROM TAIWAN
    Ou, H. T.
    Balkrishnan, R.
    Yang, C. Y.
    Chang, K. C.
    [J]. VALUE IN HEALTH, 2015, 18 (03) : A61 - A62
  • [4] Cost-Effectiveness of Newer Antidiabetic Drugs as Second-Line Treatment for Type 2 Diabetes: A Systematic Review
    Jiejin Zhu
    Ying Zhou
    Qingyu Li
    Gang Wang
    [J]. Advances in Therapy, 2023, 40 : 4216 - 4235
  • [5] Cost-Effectiveness of Newer Antidiabetic Drugs as Second-Line Treatment for Type 2 Diabetes: A Systematic Review
    Zhu, Jiejin
    Zhou, Ying
    Li, Qingyu
    Wang, Gang
    [J]. ADVANCES IN THERAPY, 2023, 40 (10) : 4216 - 4235
  • [6] Cost-Effectiveness Analysis of Empagliflozin as a Second-Line Therapy in Treatment Sequences of Patients With Type 2 Diabetes in The United States
    Reifsnider, Odette
    Kansal, Anuraag
    Pimple, Pratik
    Aponte-Ribero, Valerie
    Brand, Sarah
    Shetty, Sharash
    [J]. CIRCULATION, 2019, 140
  • [7] Second-line and third-line chemotherapy for lung cancer: Use and cost
    Ramsey, Scott D.
    Martins, Renato G.
    Blough, David K.
    Tock, Lauri S.
    Lubeck, Deborah
    Reyes, Carolina M.
    [J]. AMERICAN JOURNAL OF MANAGED CARE, 2008, 14 (05): : 297 - 306
  • [8] Cost-effectiveness analysis of cetuximab as third-line treatment in metastatic colorectal cancer
    Romeo, M.
    Soler, G.
    Martinez Villacampa, M.
    Laquente, B.
    Lopez Doriga, A.
    Pisa, A.
    Rey, M.
    Santos, C.
    Salazar, R.
    Germa Lluch, J. R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [9] Cost-effectiveness analysis of second-line pharmacological treatment of acromegaly in Spain
    Peral, Carmen
    Cordido, Fernando
    Gimeno-Ballester, Vicente
    Mir, Nuria
    Sanchez-Cenizo, Laura
    Rubio-Rodriguez, Dario
    Rubio-Terres, Carlos
    [J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2020, 20 (01) : 105 - 114
  • [10] Cost-effectiveness of second-line empagliflozin versus liraglutide for type 2 diabetes in the United States
    Reifsnider, Odette S.
    Pimple, Pratik
    Brand, Sarah
    Washington, Evelien Bergrath
    Shetty, Sharash
    Desai, Nihar R.
    [J]. DIABETES OBESITY & METABOLISM, 2022, 24 (04): : 652 - 661
12345